Company Focus
Moderna
Latest Moderna News
Biotechnology
Moderna has reported third-quarter 2024 revenues of $1.9 billion, marking a slight increase from the $1.8 billion posted in the same period in 2023. 7 November 2024
Related News
Insights
Company Spotlight
A biopharma company developing products for the treatment of human disease, including immunology, metabolism, cardiology and ophthalmology.
Latest News & Features of interest to Moderna
Biotechnology
Dallas, Texas-based Instil Bio and China’s ImmuneOnco Biopharmaceuticals have announced a license and collaboration agreement. 2 August 2024
Biotechnology
Change in on the way at California’s Vir Biotechnology. 2 August 2024
Biotechnology
Valneva (Euronext Paris: VLA) and LimmaTech Biologics have entered into a strategic partnership and exclusive licensing agreement to develop, manufacture, and commercialize Shigella4V. 2 August 2024
Biotechnology
Adaptimmune Therapeutics (Nasdaq: ADAP) has received Accelerated Approval from the US Food and Drug Administration (FDA) for Tecelra (afamitresgene autoleucel). 2 August 2024
Biotechnology
A change at the top is on the way at Cour Pharmaceuticals, a privately-held US biotech developing disease-modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases. 1 August 2024
Biotechnology
Japanese drugmaker Otsuka Pharmaceuticals is to buy privately-held US biotech Jnana Therapeutics. 1 August 2024
Pharmaceutical
Eli Lilly released positive top-line results from the SUMMIT Phase III clinical trial evaluating the safety and efficacy of tirzepatide injection in adults with heart failure with preserved ejection fraction (HFpEF) and obesity. 1 August 2024
Biotechnology
mRNA specialist Moderna (Nasdaq: MRNA) has reported a decline in revenues for the second quarter, taking in $241 million, down from $344 million in the same period last year. 1 August 2024
Biotechnology
French drugmaker Sanofi’s Genzyme subsidiary has launched legal proceedings against US biotech Sarepta Therapeutics. 1 August 2024
Biotechnology
Boston, USA-based vaccines company HilleVax has attempted to stem the tide following its announcement of disastrous norovirus trial results last month. 1 August 2024
Latest In Brief for Moderna
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Latest Relevant Ones To Watch News
California, USA-based biotech Nektar Therapeutics’ shares closed up more than 8% at $1.33 yesterday after it announced the sale of its only manufacturing facility. 5 November 2024
18 October 2024
24 September 2024
23 September 2024
16 September 2024
23 August 2024
22 August 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze